HCMR - NOVEL PREDICTORS OF OUTCOME IN HYPERTROPHIC CARDIOMYOPATHY

Registry ID

2013-1550

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

DR MATTHIAS FRIEDRICH

Start date

2014-09-03

Last update

2014-04-09

Conditions

• HYPERTROPHIC CARDIOMYOPATHY

Related clinical trials

• A PHASE 2/3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN IN A PEDIATRIC POPULATION WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• A FOLLOW-UP, OPEN-LABEL, RESEARCH EVALUATION OF SUSTAINED TREATMENT WITH AFICAMTEN (CK-3773274) IN HYPERTROPHIC CARDIOMYOPATHY (HCM)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE MAVACAMTEN ADOLESCENTS (AGE 12 YEARS TO < 18 YEARS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

View on source registry